Abstract 182P
Background
Ovarian cancer (OvCa) is one of the most prevalent cancers affecting women, with 5-year survival rates below 40%. Thus, it becomes imperative to deepen our comprehension of disease heterogeneity and progression. Within this context, the extraction of tumor cell aggregates from the solid tumor mass and the ascitic fluid offers a unique opportunity for a direct comparison of the two compartments. The identification of immune targets could provide guidance for immunotherapeutic strategies in the management of recurrent OvCa.
Methods
As part of debulking surgery, samples of solid tumor tissue and ascites were obtained from a cohort of 16 patients diagnosed with serous OvCa. Cell aggregates (ø 40-100μm) were isolated and cryo-preserved. Afterwards, specimens were subjected to a multi-parametric flow cytometric analysis, encompassing markers related to tumor (stem) characteristics and immunological features. Samples were scored by expression of plasticity markers (CD10, CD24, CD90, CD133) and immune markers (PD-L1, PD-L2, PVR, PVRL2, CD47, Calreticulin, CD39, CD73, HLA-A/B/C, HLA-DR/DP/DQ) were compared between groups of varying plasticities.
Results
Overall, ligands for co-inhibitory T-cell-receptors PD-L1 and PVR, as well as phagocytosis-associated molecules CD47 and Calreticulin were more highly expressed by tumor cells isolated from ascites, rather than solid tumors. Furthermore, EpCAM+ tumor cell subsets displaying ≥1 plasticity marker showed significantly higher levels of the investigated immunological targets. These findings were confirmed in a set of matched samples (n=4).
Conclusions
Our data indicates elevated levels of plasticity in cell aggregates derived from solid tumors. Immunogenicity markers, however, were more abundantly expressed by ascites-derived tumor cells. Given the frequent association of ascites with the dissemination and recurrence of OvCa, individuals with advanced-stage disease may benefit most from personalized immunotherapeutic interventions. Functional testing using patient-specific co-cultures of ascites-derived cell aggregates and immune cells could offer a path toward pre-therapeutic identification of patients, likely to respond to immunotherapeutic treatments.
Legal entity responsible for the study
The authors.
Funding
2cureX GmbH and BMBF funding.
Disclosure
L.S. Hell, T. Sturmheit, J. Kupper: Financial Interests, Personal, Full or part-time Employment: 2cureX GmbH. W.M. Fiedler: Non-Financial Interests, Personal, Other: AbbVie; Financial Interests, Personal, Research Grant: Amgen, Pfizer. B. Schmalfeldt: Financial Interests, Personal, Advisory Board: AstraZeneca, Roche, MSD, Eisai, GSK, Olympus; Financial Interests, Personal, Research Funding: Roche, MSD, GSK, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
100P - Phase II trial of tislelizumab plus bevacizumab and chemotherapy as the first-line therapy for persistent, recurrent, or metastatic cervical cancer: updated efficacy and safety results
Presenter: Jianqing Zhu
Session: Poster Display
101P - Progression-Free Survival is an acceptable surrogate endpoint for chemo-immunotherapy combinations in Cervical Carcinoma, an EORTC Young GCG study
Presenter: Ramon Yarza
Session: Poster Display
102P - Interim safety analysis of a phase 2 trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer
Presenter: Oladapo Yeku
Session: Poster Display
103P - Long-term survivorship rates among previously treated patients with advanced renal cell carcinoma (aRCC) achieving objective response with nivolumab
Presenter: Saby George
Session: Poster Display
105P - Preliminary efficacy and safety results from ‘ReBirth’, a phase II study of risk-based bladder-sparing therapy for MIBC.
Presenter: Yijun Shen
Session: Poster Display
106P - Treatment Sequencing in PD-L1-Positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Exploratory Analysis of the Phase 3 KEYNOTE-048 Study
Presenter: Amanda Psyrri
Session: Poster Display
108P - Real-world (RW) effectiveness and safety of adjuvant nivolumab (NIVO) in patients (pts) with melanoma in Belgium and Luxembourg: PRESERV MEL
Presenter: Bart Neyns
Session: Poster Display
109P - Prognosis of patients with metastatic melanoma with initial stable disease during treatment with anti-PD-1 monotherapy
Presenter: Inge Noringriis
Session: Poster Display
110P - Outcomes of CUPem: A prospective Phase II multicentre clinical Trial of Pembrolizumab in patients with pre-treated Cancer of Unknown Primary
Presenter: Harpreet Wasan
Session: Poster Display